← Insulet overview

Insulet vs Intuitive Surgical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Insulet Corporation (PODD)

Q3 2026
▲2▼2

Insulet's innovation advances but safety, legal, and growth risks mount

  • Next-gen Omnipod 6 and type 2 system show strong trial results Insulet's next-generation Omnipod 6 and a closed-loop system for type 2 diabetes delivered strong trial results, signaling a promising product pipeline that could drive future growth.

    Highlights a key positive development that could support future revenue.

  • Omnipod 5 maintains rapid growth Omnipod 5 continued its rapid growth with 33% revenue growth and a 25% larger customer base, demonstrating strong demand for the current flagship product.

    Shows ongoing strong performance of the core product.

  • FDA Class I recall raises safety and regulatory concerns The FDA classified a recall of certain Omnipod devices as Class I due to a cannula tear causing insulin under-delivery, raising serious safety and regulatory concerns that could harm reputation and sales.

    A major regulatory setback with potential financial and reputational impact.

  • Guidance cut and downgrade on slowing growth and competition Insulet cut 2026 revenue growth guidance to 20-22% on weak U.S. Type 2 retention, and JPMorgan downgraded the stock to Neutral, slashing its price target to $152 from $275, citing slowing growth, rising attrition, and competition.

    Directly impacts investor expectations and stock valuation.

July 2026
▲2▼2

Insulet's innovation advances but safety, legal, and growth risks mount

  • Next-gen Omnipod 6 and type 2 system show strong trial results Insulet's next-generation Omnipod 6 and a closed-loop system for type 2 diabetes delivered strong trial results, signaling a promising product pipeline that could drive future growth.

    Highlights a key positive development that could support future revenue.

  • Omnipod 5 maintains rapid growth Omnipod 5 continued its rapid growth with 33% revenue growth and a 25% larger customer base, demonstrating strong demand for the current flagship product.

    Shows ongoing strong performance of the core product.

  • FDA Class I recall raises safety and regulatory concerns The FDA classified a recall of certain Omnipod devices as Class I due to a cannula tear causing insulin under-delivery, raising serious safety and regulatory concerns that could harm reputation and sales.

    A major regulatory setback with potential financial and reputational impact.

  • Guidance cut and downgrade on slowing growth and competition Insulet cut 2026 revenue growth guidance to 20-22% on weak U.S. Type 2 retention, and JPMorgan downgraded the stock to Neutral, slashing its price target to $152 from $275, citing slowing growth, rising attrition, and competition.

    Directly impacts investor expectations and stock valuation.

Latest
▼3

Insulet's U.S. Type 2 Weakness and Legal Woes Weigh on Outlook

  • Securities fraud class action expands with multiple law firm filings Several law firms filed or reminded investors of a securities fraud class action alleging Insulet misled about Omnipod safety and manufacturing. The August 31 lead plaintiff deadline keeps legal risk in focus, which can pressure the stock as investors weigh potential costs and reputational damage.

    This is a new legal development that adds to regulatory risk and could hurt investor confidence.

  • Insulet cuts 2026 revenue growth guidance on weak U.S. Type 2 retention Insulet lowered its 2026 revenue growth outlook to 20-22% from a prior forecast, citing lower-than-expected use and retention among U.S. Type 2 diabetes customers. Although Q2 revenue beat estimates, the reduced guidance signals weaker future demand, which pushes the stock down.

    This is a new guidance cut that directly reduces expected future revenue and earnings.

  • JPMorgan downgrades Insulet to Neutral, slashes price target to $152 JPMorgan downgraded Insulet to Neutral from Overweight and cut its price target to $152 from $275, citing slowing U.S. growth, rising Type 2 attrition, and competition. The downgrade reflects a more cautious view on 2027, which can lead to selling pressure and lower valuation.

    This is a new analyst downgrade that directly impacts investor sentiment and valuation.

▼2▲1

Insulet's strong sales offset by FDA Class I recall and fraud lawsuit

  • Next-gen Omnipod 6 shows strong trial results Insulet reported positive clinical trial results for its next-generation Omnipod 6 automated insulin delivery system and a fully closed-loop system for type 2 diabetes. The trial showed up to 50% more automated insulin delivery and fewer manual boluses. This innovation could drive future demand and support long-term growth, pushing the stock up.

    New product pipeline news that could boost future revenue and investor confidence.

  • FDA Class I recall of Omnipod devices The FDA classified a recall of certain Omnipod 5, DASH, and Eros insulin pumps as Class I, the most serious type, due to a cannula tear that can cause insulin leakage and under-delivery. This raises safety concerns, may lead to regulatory scrutiny, and could hurt sales and reputation, pushing the stock down.

    A major regulatory setback that directly threatens patient safety and future revenue.

  • Securities fraud class action lawsuit filed A securities fraud class action lawsuit alleges Insulet misled investors about product safety and manufacturing quality. The lawsuit follows two product corrections in 2026 that caused stock drops. Legal costs and potential damages could weigh on the stock, and the lawsuit may keep investors cautious.

    New legal risk that could result in financial penalties and further erode investor trust.

  • Strong Omnipod 5 momentum vs. competition and macro headwinds Omnipod 5 continues to grow rapidly, with 33% revenue growth and a 25% larger customer base. However, intensifying competition and higher raw material and shipping costs from the Middle East conflict could limit profit margins. The strong demand supports the stock, but these headwinds may cap gains.

    Balances the positive sales momentum against real pressures that could affect profitability.

Intuitive Surgical Inc (ISRG)

Q3 2026
▲2▼2

Intuitive Surgical Beat Q2, But Competition and Recalls Weighed

  • Strong Q2 Beat and Momentum Intuitive Surgical beat Q2 2026 expectations with 19% revenue growth to $2.89 billion, 16% procedure growth, and adjusted EPS of $2.80. Momentum continued into August–October: system placements rose 18%, recurring revenue reached ~85% of sales, and record free cash flow of $1.8 billion funded buybacks and R&D.

    This shows the core financial and operational strength that drove the stock during the period.

  • New Growth Engines and International Expansion The Ion and single-port SP platforms emerged as new growth engines, while international expansion in India, Japan, and Malaysia offset China weakness.

    This highlights new sources of growth that supported the stock.

  • U.S. Procedure Slowdown and Recall U.S. procedure growth slowed to 12% amid ACA subsidy expirations and GLP-1-driven bariatric declines. A Class II recall of 454 da Vinci units and tariff threats pressured margins and shares.

    This explains key headwinds that weighed on the stock.

  • Competition and Governance Concerns J&J's FDA-approved Ottava robot now directly challenges da Vinci's market dominance. Additionally, valuation remains stretched versus peers, and new bylaws limit shareholder influence over governance.

    This points to competitive and governance risks that could pressure the stock.

August 2026
▲3▼1

Intuitive Surgical's August: Strong Procedures, Cash Flow, and Global Push

  • Procedure and System Growth Worldwide procedures rose 16% and system placements climbed 18%, with recurring revenue now about 85% of sales. This steady stream of recurring revenue supports the stock.

    This point highlights the core operational strength that drove the stock.

  • New Growth Engines and Cash Flow The Ion platform and single-port SP robot are emerging as second growth engines. Record free cash flow of $1.8 billion, up 71%, funds buybacks and research, boosting investor confidence.

    This point shows diversification and financial health that support the stock.

  • International Expansion Offsets China Weakness Expansion in India, Japan, and Malaysia offsets weakness in China, where local competition and pricing pressure limited placements to just two systems. This geographic diversification supports overall growth.

    This point explains how international growth mitigates regional challenges.

  • Valuation and Governance Concerns Valuation is debated with fair value estimates of $439–$630 and a P/E well above peers. New bylaws make it harder for shareholders to force governance changes, limiting investor influence.

    This point highlights key risks that could weigh on the stock.

Latest
▲3

Intuitive Surgical: overseas expansion and new platforms offset China weakness

  • India and Japan expansion offsets China drag Da Vinci 5 was cleared in India, and Japan expanded reimbursement for more robotic procedures, helping Intuitive place 25 systems there versus 15 a year earlier. International procedures grew 20%, easing the blow from China, where only two systems were placed amid local competition and pricing pressure.

    This is the clearest new force behind ISRG's growth outlook, showing where future revenue is coming from as China stalls.

  • Single-port platform nears billion-dollar franchise Single-port procedures jumped 61% year over year, with 38 systems placed and U.S. utilization up 25%. The SP stapler is used in nearly 60% of eligible U.S. cases, up from under 40%. This gives Intuitive a second fast-growing robot line beyond its main multi-port business.

    It shows a new, fast-growing product line that adds durable revenue and reduces reliance on the core da Vinci business.

  • Long-term investors back growth despite weak stock Baron Capital expects mid-teens revenue growth for years, and TCW Funds cited Intuitive's 20-year lead, strong moat, buybacks and raised guidance. Both looked past a rough stretch in which the stock fell sharply, signaling that professional investors see the decline as temporary.

    It explains why sentiment may be stabilizing and gives a counterweight to the negative price action readers have seen.

  • Valuation debate and tighter governance rules Analysts put fair value anywhere from about $439 to $630, with some calling the stock cheap and others noting its price-to-earnings ratio is well above peers. New bylaws also make it harder for unhappy shareholders to force changes, which could keep management stable but limits investor influence.

    It captures the real counterweight: the stock is not obviously cheap, and governance changes cut both ways.

▲4

Intuitive Surgical: Procedure Growth, New Approvals, and Cash Strength Drive Upside

  • Procedure Growth and System Placements Accelerate Worldwide procedures rose 16% and da Vinci system placements jumped 18% to 468, with U.S. placements up 24%. This shows hospitals are still buying and using Intuitive's robots, which drives recurring revenue and future sales. The stock benefits because growth is durable despite concerns about a U.S. slowdown.

    This is the core demand driver that directly supports revenue and earnings growth, which pushes the stock up.

  • Ion Platform Emerges as Second Growth Engine Ion procedures surged 36% to 48,000, cumulative procedures passed 400,000, and the installed base grew 21% annually. This new lung-cancer diagnosis platform gives Intuitive another source of recurring revenue, reducing reliance on da Vinci and supporting a higher stock valuation.

    It highlights a new, fast-growing revenue stream that diversifies the business and boosts long-term growth prospects.

  • Record Cash Flow Fuels Innovation and Buybacks First-half free cash flow jumped 71% to $1.8 billion, and the company bought back $379 million of stock. Strong cash gives Intuitive flexibility to invest in R&D, expand manufacturing, and return money to shareholders, which supports the stock price by signaling financial health and confidence.

    It shows the company's financial strength and ability to fund growth without sacrificing shareholder returns, a key positive for the stock.

  • Clinical Evidence and New Regulatory Approval Expand Use A landmark meta-analysis showed da Vinci surgery improves outcomes across 13 conditions, and a new CE mark allows transvaginal gynecology with da Vinci SP in Europe. These strengthen the case for adoption, open new markets, and support premium pricing, all of which can lift the stock.

    It provides scientific validation and regulatory expansion that can drive broader adoption and pricing power, directly impacting future revenue.

▲3

ISRG: Solid Procedure Growth and New Products Offset Rising Robot Competition

  • Recurring revenue and procedure growth remain strong Worldwide procedures rose about 16% and system placements jumped 18% to 468, with recurring instrument and service revenue now roughly 85% of sales. That steady, repeat business supports ISRG's price even when headline growth slows.

    Shows the core demand engine still growing, the main support for the stock.

  • Analyst upgrades and software moat reinforce confidence Oppenheimer upgraded ISRG to Outperform with a $500 target, and UBS called the selloff overdone. The company is rolling out 100+ da Vinci 5 software updates and filed for FDA clearances, deepening its technology lead and supporting the stock.

    New analyst actions and product roadmap directly lift investor sentiment and the stock.

  • New Malaysia plant expands supply for Asia growth ISRG will build a 316,000-square-foot manufacturing facility in Penang, Malaysia, starting operations in 2028 and creating 1,200 jobs. This adds capacity for surgical instruments and supports long-term growth in Asia Pacific, a positive for the stock.

    New capacity investment signals confidence and future supply expansion.

July 2026
▼3▲1

Intuitive Surgical Q2 Beat Marred by Recall, Slowdown, and New Rival

  • Q2 Beat and Procedure Growth Intuitive Surgical beat Q2 2026 expectations with revenue up 19% to $2.89 billion, adjusted EPS of $2.80, and 16% worldwide procedure growth. This drove recurring instrument and service revenue, supporting the stock.

    This is the main positive fundamental driver for the period.

  • U.S. Procedure Growth Slowdown U.S. procedure growth slowed to 12% as ACA subsidy expirations left patients uninsured, and GLP-1 drugs reduced bariatric surgeries. This weighed on overall growth and investor sentiment.

    This explains a key negative trend affecting demand.

  • Class II Recall and Tariff Threats A Class II recall of 454 da Vinci units raised regulatory and cost concerns, sending shares down 6.3%. Tariffs also threaten margins, with management warning they could materially alter results.

    These are major negative events that pressured the stock.

  • Competition from J&J's Ottava J&J's FDA-approved Ottava robot now directly challenges da Vinci, threatening market share and pricing power. This competitive threat adds to concerns about future growth.

    This is a new competitive development with negative implications.

▼4

ISRG Plunges on Slowing US Procedures, GLP-1 Headwinds, and New J&J Competition

  • US Procedure Growth Slows on Insurance and GLP-1 US da Vinci procedure growth slowed to 12% from 14% as ACA subsidy expirations left patients uninsured and GLP-1 weight-loss drugs cut bariatric surgeries. This reduces recurring revenue from instruments and services, pressuring ISRG's stock.

    This is the core reason for the stock's decline and the main new negative driver this period.

  • J&J's Ottava Robot Enters US Market Johnson & Johnson received FDA approval for its Ottava surgical robot, directly challenging Intuitive's da Vinci in soft-tissue surgery. This raises competition and could limit ISRG's market share and pricing power, weighing on the stock.

    A new competitive threat that changes the long-term outlook for ISRG's dominance.

  • Full-Year Procedure Growth Guided to Middle of Range Management said full-year procedure growth will likely be near the middle of its 13.5-15.5% range, not the high end. This disappointed investors who expected stronger growth, leading to a sharp sell-off.

    Guidance cut is a key new negative catalyst that drove the stock down.

  • Tariff Headwinds Could Materially Alter Results Intuitive warned that additional tariffs could materially alter its financial results, adding cost pressure. Tariffs raise expenses for imported components, which can squeeze profit margins and reduce earnings.

    Tariff risk is a new explicit warning that adds uncertainty to future profits.

▼3▲1

Intuitive Beats Q2 but Insurance and Tariff Worries Sink Shares

  • Q2 Beat on Procedure Growth and da Vinci 5 Placements Intuitive reported Q2 revenue of $2.89 billion, up 19%, and adjusted EPS of $2.80, both beating expectations. Worldwide procedures grew 16%, with 246 da Vinci 5 systems placed. More procedures and system placements drive recurring instrument and service revenue, directly boosting ISRG's sales and profit.

    This is the core new financial result that shows the company's underlying business is still growing strongly.

  • U.S. Procedure Growth Slows on Insurance Changes U.S. da Vinci procedure growth slowed to 12% as patients lost health insurance after ACA tax credits expired. Management warned this could weigh on demand, and analysts cut price targets. Slower U.S. procedure growth means less recurring revenue from instruments and services, pressuring ISRG's stock.

    This is the main new negative that caused the stock to drop over 9% despite the earnings beat.

  • Class II Recall of da Vinci Components Intuitive issued a voluntary Class II recall of certain da Vinci components due to an E-brake retainer pin issue, affecting 454 units. The recall raises operational and regulatory scrutiny, and the stock fell 6.3% on the news. It adds uncertainty ahead of earnings and could lead to higher costs or reputational damage.

    This is a new negative event that directly hit the stock price and raises questions about product quality and regulatory risk.

  • Tariff-Related Margin Pressure Flagged Intuitive maintained its full-year procedure growth outlook of 13.5-15.5% but flagged tariff-related margin pressure. Tariffs add costs to imported components, which can squeeze profit margins. The company also noted a $28 million tariff refund benefit this quarter, but future tariffs remain a headwind.

    This is a new cost concern that weighs on profitability and was cited as a reason for the stock's decline.

Q2 2026
▲2▼1

Intuitive Surgical Raises Procedure Outlook, But Competition and Valuation Loom

  • Procedure Growth Guidance Raised Intuitive Surgical raised its 2026 procedure growth outlook to 13.5-15.5%, driven by strong U.S. general surgery and international adoption. More procedures mean more recurring revenue from instruments and services, directly boosting ISRG's sales and profit.

    This is a new, concrete positive catalyst that directly affects future revenue and earnings.

  • Competition Warning from Jim Cramer Jim Cramer warned that Intuitive Surgical now faces serious competition from Johnson & Johnson and Medtronic in robotic surgery. If rivals gain ground, ISRG could lose market share and pricing power, weighing on future growth and the stock price.

    This is a new, credible negative view that highlights a key risk to ISRG's dominant market position.

  • AI Moat Reinforcement Intuitive Surgical is using its vast da Vinci procedure data to enhance safety and effectiveness with AI, strengthening its competitive edge. This could widen its lead over rivals and support long-term pricing and adoption, a positive for the stock.

    This is a new angle on how ISRG leverages technology to defend its market leadership.

  • Valuation and Analyst Sentiment ISRG trades at 50 times earnings, above Nvidia but below its own five-year average, while holding a Zacks Rank #2 (Buy) with steady estimates. The premium valuation could limit upside, but strong fundamentals and analyst confidence provide support.

    This new valuation comparison and analyst rating help investors gauge whether the stock is expensive or still attractive.

June 2026
▲2▼1

Intuitive Surgical Raises Procedure Outlook, But Competition and Valuation Loom

  • Procedure Growth Guidance Raised Intuitive Surgical raised its 2026 procedure growth outlook to 13.5-15.5%, driven by strong U.S. general surgery and international adoption. More procedures mean more recurring revenue from instruments and services, directly boosting ISRG's sales and profit.

    This is a new, concrete positive catalyst that directly affects future revenue and earnings.

  • Competition Warning from Jim Cramer Jim Cramer warned that Intuitive Surgical now faces serious competition from Johnson & Johnson and Medtronic in robotic surgery. If rivals gain ground, ISRG could lose market share and pricing power, weighing on future growth and the stock price.

    This is a new, credible negative view that highlights a key risk to ISRG's dominant market position.

  • AI Moat Reinforcement Intuitive Surgical is using its vast da Vinci procedure data to enhance safety and effectiveness with AI, strengthening its competitive edge. This could widen its lead over rivals and support long-term pricing and adoption, a positive for the stock.

    This is a new angle on how ISRG leverages technology to defend its market leadership.

  • Valuation and Analyst Sentiment ISRG trades at 50 times earnings, above Nvidia but below its own five-year average, while holding a Zacks Rank #2 (Buy) with steady estimates. The premium valuation could limit upside, but strong fundamentals and analyst confidence provide support.

    This new valuation comparison and analyst rating help investors gauge whether the stock is expensive or still attractive.

▲2▼1

Intuitive Surgical Raises Procedure Outlook, But Competition and Valuation Loom

  • Procedure Growth Guidance Raised Intuitive Surgical raised its 2026 procedure growth outlook to 13.5-15.5%, driven by strong U.S. general surgery and international adoption. More procedures mean more recurring revenue from instruments and services, directly boosting ISRG's sales and profit.

    This is a new, concrete positive catalyst that directly affects future revenue and earnings.

  • Competition Warning from Jim Cramer Jim Cramer warned that Intuitive Surgical now faces serious competition from Johnson & Johnson and Medtronic in robotic surgery. If rivals gain ground, ISRG could lose market share and pricing power, weighing on future growth and the stock price.

    This is a new, credible negative view that highlights a key risk to ISRG's dominant market position.

  • AI Moat Reinforcement Intuitive Surgical is using its vast da Vinci procedure data to enhance safety and effectiveness with AI, strengthening its competitive edge. This could widen its lead over rivals and support long-term pricing and adoption, a positive for the stock.

    This is a new angle on how ISRG leverages technology to defend its market leadership.

  • Valuation and Analyst Sentiment ISRG trades at 50 times earnings, above Nvidia but below its own five-year average, while holding a Zacks Rank #2 (Buy) with steady estimates. The premium valuation could limit upside, but strong fundamentals and analyst confidence provide support.

    This new valuation comparison and analyst rating help investors gauge whether the stock is expensive or still attractive.